KALV

KalVista Pharmaceuticals (KALV)

About KalVista Pharmaceuticals (KALV)

KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: Sebetralstat for HAE and Factor XIIa. The company was founded by T. Andrew Crockett, Edward P. Feener, and Lloyd Paul Aiello on March 26, 2004 and is headquartered in Cambridge, MA.

Details

Daily high

$12.10

Daily low

$11.61

Price at open

$11.68

52 Week High

$15.50

52 Week Low

$7.30

Market cap

593.1M

Dividend yield

0.00%

Volume

413,615

Avg. volume

490,388

P/E ratio

-3.20

KalVista Pharmaceuticals News